Dyslipidemias
Conditions
Brief summary
This observation study is to evaluate blood lipid-lowering effects and liver/renal safety, changes in HbA1c and FPG in patients with dyslipidemia who administered CREZET tablets for 24 weeks.
Detailed description
A subject who is diagnosed with dyslipidemia and scheduled to administer CREZET tablets, will be enrolled in this study based on the doctor's medical decision. The CREZET Tablet will be administered for 24 weeks, and the data including demographic information, body measurement, vital signs and etc will be collected during the study period. The data collection point is as follows. 1. Visit 1 (baseline, day 0) 2. Visit 2 (at 12 weeks) 3. Visit 3 (at 24 weeks)
Interventions
Patient treated with Crezet Tablet
Sponsors
Daewoong Pharmaceutical Co. LTD.
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. an adult male and female over 19 years of age 2. A patient with dyslipidemia who is scheduled to administer Crezet tablets according to the medical judgment of the investigator based on permission 3. A person who voluntarily participates in the observational study and agrees in writing to comply with the subject's precautions during the study period after hearing and understanding the detailed explanation of the characteristics of the observational study and the drug to be studied
Exclusion criteria
1. A person who is prohibited from administering according to the permission of the Crezet definition * Patients who overreact to the principal or component of the Crezet definition * Patients with active liver disease or patients with persistent high symptoms of serum aminotransferase levels * a patient with a muscle disease * a patient administered in combination with a cyclosporine-med * Patients with severe renal failure (Creatinine Clearance (CLcr) \< 30 mL/min) * Women and lactating women who may be pregnant or pregnant * Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption 2. A person who has a history of taking Crezet tablets within three months of the date of registration 3. A person who is deemed inappropriate to participate in this observational study based on the judgment of investigator.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Rate of change in LDL-C | 24 weeks | The Rate of change in LDL-C at 24 weeks from baseline |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The change in HbA1c | 12 weeks | The change in HbA1c at 12 weeks from baseline |
| The change in FPG | 12 weeks | The change in FPG at 12 weeks from baseline |
| The chanage in lipid variable | 12 weeks | The chanage in lipid variable at 12 weeks from baseline |
| The Rate of change in LDL-C | 12 weeks | The Rate of change in LDL-C at 12 weeks from baseline |
| The change in ALT | 12 weeks | The change in ALT at 12 weeks from baseline |
| Percentage of subjects who reached LDL-C target | 12 weeks | Percentage of subjects who reached LDL-C target according to Korean Society of Lipid Arteriosclerosis's risk classification of treatment guidelines for dyslipidemia at 12 weeks from baseline |
| The change in AST | 12 weeks | The change in AST at 12 weeks from baseline |
Countries
South Korea
Outcome results
None listed